Coeptis Therapeutics (COEP) Competitors

Coeptis Therapeutics (NASDAQ:COEP) and Greenwich LifeSciences (NASDAQ:GLSI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, community ranking, risk, valuation, analyst recommendations, dividends, earnings and profitability.

Is COEP or GLSI more profitable?

Greenwich LifeSciences' return on equity of -185.12% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coeptis Therapeutics	N/A	-1,094.50%	-219.97%
Greenwich LifeSciences	N/A	-185.12%	-164.27%

Do analysts rate COEP or GLSI?

Greenwich LifeSciences has a consensus price target of $39.00, suggesting a potential upside of 305.57%. Given Greenwich LifeSciences' stronger consensus rating and higher possible upside, analysts plainly believe Greenwich LifeSciences is more favorable than Coeptis Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coeptis Therapeutics	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Greenwich LifeSciences	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the MarketBeat Community prefer COEP or GLSI?

Greenwich LifeSciences received 4 more outperform votes than Coeptis Therapeutics when rated by MarketBeat users. However, 71.43% of users gave Coeptis Therapeutics an outperform vote while only 47.37% of users gave Greenwich LifeSciences an outperform vote.

Company	Underperform	Outperform
Coeptis Therapeutics	Outperform Votes 5 71.43%	Underperform Votes 2 28.57%
Greenwich LifeSciences	Outperform Votes 9 47.37%	Underperform Votes 10 52.63%

Do insiders & institutionals have more ownership in COEP or GLSI?

13.9% of Coeptis Therapeutics shares are owned by institutional investors. Comparatively, 4.2% of Greenwich LifeSciences shares are owned by institutional investors. 24.3% of Coeptis Therapeutics shares are owned by insiders. Comparatively, 51.7% of Greenwich LifeSciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Which has better valuation & earnings, COEP or GLSI?

Greenwich LifeSciences has lower revenue, but higher earnings than Coeptis Therapeutics. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Coeptis Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coeptis Therapeutics	$62.87K	482.33	-$21.27M	-$5.80	-1.49
Greenwich LifeSciences	N/A	N/A	-$8.89M	-$1.26	-7.63

Does the media refer more to COEP or GLSI?

In the previous week, Coeptis Therapeutics and Coeptis Therapeutics both had 1 articles in the media. Coeptis Therapeutics' average media sentiment score of 1.87 equaled Greenwich LifeSciences'average media sentiment score.

Company	Overall Sentiment
Coeptis Therapeutics	Very Positive
Greenwich LifeSciences	Very Positive

Which has more volatility and risk, COEP or GLSI?

Coeptis Therapeutics has a beta of -0.59, suggesting that its stock price is 159% less volatile than the S&P 500. Comparatively, Greenwich LifeSciences has a beta of 1.69, suggesting that its stock price is 69% more volatile than the S&P 500.

Summary

Greenwich LifeSciences beats Coeptis Therapeutics on 10 of the 14 factors compared between the two stocks.